Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Recording warning: Common brain signal may be misunderstood
High gamma activity in electrophysiologic recordings reflects widespread neural activity, not merely local firing, as previously thought.
Recording warning: Common brain signal may be misunderstood
High gamma activity in electrophysiologic recordings reflects widespread neural activity, not merely local firing, as previously thought.
Fructose silences hunger-driving neurons less than glucose does
Two simple sugars show the complexities of gut-brain communication.
Fructose silences hunger-driving neurons less than glucose does
Two simple sugars show the complexities of gut-brain communication.
A new subtyping model for autism phenotypes late in development, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 29 June.
A new subtyping model for autism phenotypes late in development, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 29 June.